Fluxid FDA Approval History
FDA Approved: Yes (Discontinued) (First approved September 24, 2004)
Brand name: Fluxid
Generic name: famotidine
Dosage form: Orally Disintegrating Tablets
Company: Schwarz Pharma, Inc.
Treatment for: Duodenal Ulcer, Stomach Ulcer, GERD, Zollinger-Ellison Syndrome
Marketing Status: Discontinued
Fluxid (famotidine orally disintegrating tablets) is a histamine H2-receptor antagonist indicated for the treatment of ulcers, gastroesophageal reflux disease and pathological hypersecretory conditions.
Development Timeline for Fluxid
|Sep 24, 2004||Fluxid Schwarz Pharma, Inc. - Treatment for Ulcers and other Gastrointestinal Conditions|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.